glp 1 agonists oral Lesson: Semaglutide: A New GLP-1 Receptor Agonist Product for the Treatment of Type 2 Diabetes Comparison of GLP-1 receptor agonists

Description

Hidalgo, D

Although neither the DSM nor the International Classification of Diseases (ICD) formally recognizes addiction to highly palatable foods as a clinical diagnosis (LaFata et al., 2025), there is nevertheless a notable parallel between substance use disorders and certain patterns of eating behavior

The effects of this presentation on weight and glycemia in clinical trials and real-world settings are comparable to those induced by the subcutaneous presentation, although a specific indication for weight control without DT2 is still lacking.86 In order to avoid confusion in daily clinical practice, it is important to note that liraglutide 3mg and semaglutide 2.4mg can be used in patients with DT2, provided these are obese or overweight with comorbidities

32 On the other hand, local hepatic lipid metabolism is regulated by sympathetic neural signals through the brain-liver axis, while glucose metabolism receives CNS regulation, although the signaling pathways remain unclear

As such, the answer to this question pertains to everything from a patients decision to use a GLP-1 medication or a providers likelihood of prescribing one, to health plans and employers coverage decisions, and investment strategies for companies ranging from consumer products to pharma